CTXR NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Citius Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 0.52 USD
4.9% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -27.3% below the Trend Line and sits at 3.0% of its 52-week range. The latest completed week returned 4.9%, after a -3.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 26/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: earnings are due in 13d.

Setup score 21 out of 100
Latest Close 0.52 USD 24 Jul 2026
1W Return 4.9% latest completed week
4W Return -3.6% short-term follow-through
12W Return -25.7% quarterly tape
Trend Breadth 13.5% 7 of 52 weeks active
Volume Ratio 1.3x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.9% Latest completed week; four-week move -3.6%. Indicator stack 7/37 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.83% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 26/100 conviction; expected move 59.4%. News sentiment 53/100 61 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -27.3% below the Trend Line and sits at 3.0% of its 52-week range. The latest completed week returned 4.9%, after a -3.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1212-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.12Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.6% over four weeks, -25.7% over 12 weeks, and -68.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.9%
4W-3.6%
12W-25.7%
26W-38.8%
52W-68.8%
Active trend streak0 weeks
Active weeks in one year7
Trend breadth13.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.75Latest activity-pressure read.
Pressure change1.0%Four-week change in activity pressure.
Leadership-50.63Latest relative-leadership reading.
RS change8.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Sep 2025 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value58/100Relative valuation strength. Underlying universe rank 43; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum58/100Medium-term price momentum. Underlying universe rank 43; rank 1 is best.
Growth58/100Revenue and earnings growth. Underlying universe rank 43; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
2.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-175.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
37.4%
Gross profit retained from each unit of revenue.
Operating margin
-1040.1%
Operating profit retained from revenue.
Free-cash-flow margin
-563.1%
Free cash flow generated from revenue.
Return on invested capital
-75.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

CTXR shows mixed options pressure with a 26/100 conviction score, put-call volume ratio of n/a, expected move of 59.4%, and Sharemaestro trend signal inactive.

Conviction26/100
Expected move59.4%
Put/call volume
Pressure11
Speculation0
Volatility96
Trend agreement44
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 61 relevant articles.

13 positive · 42 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move59.4%Nearest-chain priced movement where available.
52-week drawdown-76.2%Distance below the 52-week high.
13-week volatility7.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+18.8%Week of 3 Apr.
Worst week-19.9%Week of 20 Mar.
Latest week+4.9%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses2
Sharp losses11
Recent vol7.4%13-week weekly-return volatility.
Base vol11.9%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew9.3% / -9.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis19/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.12; No reversal markers Next-Week ExpectancyNegative 39.83%

Next-week expectancy is negative with a 39.83% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options41/100

CTXR shows mixed options pressure with a 26/100 conviction score, put-call volume ratio of n/a, expected move of 59.4%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 59.4% Sentiment53/100

Weighted news tone is neutral across 61 relevant articles.

CTXR|Citius Pharmaceuticals Inc|Price:0.505|Chg%:-0.012 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.52 USD4.9%0.72 USD8.37 USD-0.75-50.633.4MOff
17 Jul 20260.50 USD-14.9%0.73 USD8.55 USD-0.78-54.941.1MOff
10 Jul 20260.58 USD1.4%0.75 USD8.73 USD-0.79-50.47816.1KOff
3 Jul 20260.57 USD6.4%0.76 USD8.92 USD-0.80-51.44973.0KOff
26 Jun 20260.54 USD-1.2%0.78 USD9.11 USD-0.76-55.60984.2KOff
19 Jun 20260.55 USD1.2%0.81 USD9.30 USD-0.51-58.05942.4KOff
12 Jun 20260.54 USD-3.6%0.83 USD9.50 USD-0.09-58.041.7MOff
5 Jun 20260.56 USD-14.5%0.85 USD9.69 USD0.25-55.921.7MOff
29 May 20260.65 USD-6.6%0.87 USD9.88 USD0.40-51.202.6MOff
22 May 20260.70 USD0.1%0.90 USD10.09 USD0.56-46.485.7MOff
15 May 20260.70 USD9.4%0.94 USD10.26 USD0.65-46.124.4MOff
8 May 20260.64 USD-8.6%0.96 USD10.45 USD0.72-51.253.2MOff
1 May 20260.70 USD-9.1%0.98 USD10.67 USD0.85-44.136.9MOff
24 Apr 20260.77 USD-10.3%1.01 USD10.87 USD0.94-37.937.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.